NDC 71777-392 – Vitrakvi
Larotrectinib 20 mg/mL · Solution · Oral
Product NDC71777-392
Product details
- Brand name
- Vitrakvi
- Generic name
- Larotrectinib
- Labeler
- Loxo Oncology, Inc.
- Dosage form
- Solution
- Route
- Oral
- Marketing category
- NDA · NDA211710
- Marketed since
- November 26, 2018
- Listing expires
- December 31, 2026
- Pharmacologic class
- Kinase Inhibitor
Active ingredients
- Larotrectinib 20 mg/mL
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 71777-392-01 | 100 mL in 1 BOTTLE (71777-392-01) | Nov 26, 2018 |
Other Vitrakvi products
- 50419-390 Larotrectinib 25 mg/1 · Capsule · Bayer HealthCare Pharmaceuticals Inc.
- 50419-391 Larotrectinib 100 mg/1 · Capsule · Bayer HealthCare Pharmaceuticals Inc.
- 50419-392 Larotrectinib 20 mg/mL · Solution, Concentrate · Bayer HealthCare Pharmaceuticals Inc.
- 50419-393 Larotrectinib 20 mg/mL · Solution, Concentrate · Bayer HealthCare Pharmaceuticals Inc.
- 71777-390 Larotrectinib 25 mg/1 · Capsule · Loxo Oncology, Inc.
- 71777-391 Larotrectinib 100 mg/1 · Capsule · Loxo Oncology, Inc.